Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Rating Raised to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) from a strong sell rating to a sell rating in a research note published on Saturday,Wall Street Zen reports.

Other equities analysts have also recently issued research reports about the stock. William Blair initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Wednesday, September 16th. They issued an “outperform” rating on the stock. Wells Fargo & Company began coverage on shares of Zentalis Pharmaceuticals in a research report on Wednesday, September 30th. They set an “equal weight” rating and a $5.00 target price for the company. Jefferies Financial Group raised shares of Zentalis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 14th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Monday, October 19th. Finally, Rodman & Renshaw started coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $8.29.

Zentalis Pharmaceuticals Trading Up 1.2%

ZNTL stock traded up $0.02 during trading on Friday, reaching $1.70. The stock had a trading volume of 1,300,020 shares, compared to its average volume of 1,464,476. Zentalis Pharmaceuticals has a 52 week low of $1.28 and a 52 week high of $6.95. The stock’s 50 day moving average is $2.53 and its two-hundred day moving average is $3.38. The firm has a market cap of $121.84 million, a PE ratio of -0.89 and a beta of 1.91.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Monday, November 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.20. On average, research analysts anticipate that Zentalis Pharmaceuticals will post -1.80 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ZNTL. CTC Alternative Strategies Ltd. bought a new position in Zentalis Pharmaceuticals during the first quarter valued at approximately $29,000. Spark Investment Management LLC purchased a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at approximately $61,000. The Manufacturers Life Insurance Company purchased a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at approximately $69,000. State of Wyoming bought a new stake in Zentalis Pharmaceuticals in the 2nd quarter worth approximately $91,000. Finally, Sei Investments Co. increased its stake in Zentalis Pharmaceuticals by 14.6% in the 1st quarter. Sei Investments Co. now owns 191,551 shares of the company’s stock worth $448,000 after acquiring an additional 24,451 shares during the last quarter.

Key Headlines Impacting Zentalis Pharmaceuticals

These are some of the ZNTL headlines that stood out recently:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $10 price target while substantially narrowing its projected losses for 2026–2028. For example, its FY2027 EPS forecast improved to ($1.90) from ($2.76), and its FY2028 estimate improved to ($1.64) from ($2.13). The repeated reports describe the same broad estimate revisions, rather than separate analyst actions.
• Neutral Sentiment: Morgan Stanley maintained a Hold rating, indicating it did not see enough reason to change its stance. Morgan Stanley Remains a Hold on Zentalis Pharmaceuticals
• Negative Sentiment: HC Wainwright lowered its FY2029 and FY2030 EPS forecasts, to ($1.10) from ($1.00) and to ($0.42) from ($0.18), respectively. These later-year cuts partially offset its more favorable revisions for nearer-term years.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for cancer. Its research centers on therapies that target biological processes involved in tumor growth. The company’s lead drug candidate, azenosertib (formerly known as ZN-c3), is an investigational inhibitor of WEE1, a protein involved in cell-cycle regulation. It has been studied in clinical trials for ovarian cancer and other solid tumors. Zentalis has also advanced other oncology drug candidates, including compounds targeting cancer-related proteins.